Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PK14105 has been evaluated biologically as a potential radioligand for positron emission tomography (PET) studies targeting peripheral benzodiazepine binding sites (PBBS) receptors. When administered to rats with unilaterally lesioned striata, PK14105 was observed to quickly cross the blood-brain barrier, displaying significant radioactivity retention in the lesioned striatum, in contrast to the unlesioned striatum or cerebellar vermis. Additionally, PK14105 has the capability to inhibit receptor ligands, calcium channel ligands, and co-transporters in all salivary glands.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
2 mg | 約 5 days | ¥ 30,000 |
5 mg | 約 5 days | ¥ 50,000 |
25 mg | 約6-8 週間 | ¥ 167,000 |
50 mg | 約6-8 週間 | ¥ 217,500 |
100 mg | 約6-8 週間 | ¥ 342,000 |
1 mL * 10 mM (in DMSO) | 約 5 days | ¥ 45,500 |
説明 | PK14105 has been evaluated biologically as a potential radioligand for positron emission tomography (PET) studies targeting peripheral benzodiazepine binding sites (PBBS) receptors. When administered to rats with unilaterally lesioned striata, PK14105 was observed to quickly cross the blood-brain barrier, displaying significant radioactivity retention in the lesioned striatum, in contrast to the unlesioned striatum or cerebellar vermis. Additionally, PK14105 has the capability to inhibit receptor ligands, calcium channel ligands, and co-transporters in all salivary glands. |
分子量 | 381.4 |
分子式 | C21H20FN3O3 |
CAS No. | 107257-28-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (78.66 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PK14105 107257-28-3 Others PK-14105 PK 14105 Inhibitor inhibitor inhibit